Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-24
2007-04-24
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S399000, C424S198100
Reexamination Certificate
active
10200050
ABSTRACT:
Described herein are pharmaceutical compositions including vascular endothelial cell growth factor (VEGF) variants having modifications in the C-terminal heparin binding domain. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.
REFERENCES:
patent: 5073492 (1991-12-01), Chen et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5464815 (1995-11-01), Chamow et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 6020473 (2000-02-01), Keyt et al.
patent: 6057428 (2000-05-01), Keyt et al.
patent: 6100071 (2000-08-01), Davis-Smith et al.
patent: 6395707 (2002-05-01), Zioncheck et al.
patent: 0 506 477 (1992-09-01), None
patent: WO 90/13649 (1990-11-01), None
patent: WO 91/02058 (1991-02-01), None
patent: WO 95/07097 (1995-03-01), None
patent: WO 96/06641 (1996-03-01), None
patent: WO 98/10071 (1998-03-01), None
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science 247: 1306-1310, 1990.
Breier et al., “Expression of Vascular Endothelial Growth Factor During Embryonic Angiogenesis and Endothelial Cell Differentiation,” Development, 114:521-532 (1992).
Ferrara et al., “Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells,” Biophys. Res. Comm., 161:851-858 (1989).
Ferrara, N., “Vascular Endothelial Growth Factor,” Laboratory Investigation, 72(6):615-618 (1995).
Gengrinovitch et al., “Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121and VEGF165Using Several Concurrent Mechanisms” J. Biol Chem. 270(25):15059-15065, 1995.
Keyt et al. “The Carboxyl-Terminal Domain (111-165) of Vascular Endothelial Growth Factor is Critical for its Mitogenic Potency,” J. Biol Chem 271(13):7788-7795, 1996.
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” inThe Protein Folding Problem and Tertiary Structure. Merz, K. Jr. and Le Grand, S. (eds). Birkhauser, Boston, pp. 492-495, 1994.
Robson et al.Introduction to Proteins and Protein Engineering. New York, Elsevier, p. 41, 1986.
Schultz et al., Principles of Protein Structure, Springer-Verlag: New York, pp. 14-16 (1979).
Walter et al., “The In Vivo Bioactivity of Vascular Endothelial Growth Factor/Vascular Permeability Factor is Independent of N-Linked Glycosidation,” Laboratory Investigation, 74(2):546-556 (Feb. 1996).
Wells, “Additivity of Mutational Effects in Proteins,” Biochemistry 29:8509-8517, (1990).
Houck et al., 1992,The Journal of Biochemistry,267(36):26031-26037 “Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms”.
Kato et al., 1994,Hepatology,20(2):417-424 “Heparin-hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity”.
Mühlhauser et al., 1995,Circulation Research,77:1077-1086 “VEGF165Expressed by a Replication-Deficient Recombinant Adenovirus Vector-Induces AngiogenesisIn Vivo”.
Rao et al., 1983,Blood,61(6):1208-1214 “Effect of heparin on thein vivorelease and clearance of human platelet factor 4”.
DeGuzman Geralyn G.
Keck Rodney Gene
Zioncheck Thomas F.
Genentech Inc.
Merchant & Gould P.C.
Saoud Christine J.
LandOfFree
Pharmaceutical compositions including variants of vascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions including variants of vascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions including variants of vascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3763614